107 related articles for article (PubMed ID: 8235450)
1. The detection and biological activity of human antibodies to IL-2 in normal donors.
Tiberio L; Caruso A; Pozzi A; Rivoltini L; Morelli D; Monti E; Balsari A
Scand J Immunol; 1993 Nov; 38(5):472-6. PubMed ID: 8235450
[TBL] [Abstract][Full Text] [Related]
2. Natural antibodies to IL-2.
Balsari A; Caruso A
Biotherapy; 1997; 10(1):25-8. PubMed ID: 9261547
[TBL] [Abstract][Full Text] [Related]
3. Purification of interleukin-2 antibodies from healthy individuals.
Monti E; Pozzi A; Tiberio L; Morelli D; Caruso A; Villa ML; Balsari A
Immunol Lett; 1993 Jun; 36(3):261-6. PubMed ID: 8370597
[TBL] [Abstract][Full Text] [Related]
4. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2.
Horton SA; Oldham RK; Yannelli JR
Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.
Alderson MR; Sassenfeld HM; Widmer MB
J Exp Med; 1990 Aug; 172(2):577-87. PubMed ID: 2142722
[TBL] [Abstract][Full Text] [Related]
6. Humoral modulation of lymphokine-activated killer (LAK)-cell induction in humans: IgG-related and non-IgG inhibitors in sera from cancer patients.
Riley LB; Pellis NR; Schantz SP; Freedman RS; Balch CM; Itoh K
Int J Cancer; 1990 Nov; 46(5):785-91. PubMed ID: 2228306
[TBL] [Abstract][Full Text] [Related]
7. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
8. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.
Bamford RN; Grant AJ; Burton JD; Peters C; Kurys G; Goldman CK; Brennan J; Roessler E; Waldmann TA
Proc Natl Acad Sci U S A; 1994 May; 91(11):4940-4. PubMed ID: 8197161
[TBL] [Abstract][Full Text] [Related]
9. In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapies.
Sosman JA; Hank JA; Sondel PM
Semin Oncol; 1990 Feb; 17(1 Suppl 1):22-30; discussion 38-41. PubMed ID: 2405492
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapy.
Bergstrom RW; Atkins MB; Mier JW; Palmer JP
J Clin Lab Immunol; 1990 Apr; 31(4):189-93. PubMed ID: 1967063
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
Grant AJ; Merchant RE; Hall RE
Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
[TBL] [Abstract][Full Text] [Related]
12. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
Hank JA; Robinson RR; Surfus J; Mueller BM; Reisfeld RA; Cheung NK; Sondel PM
Cancer Res; 1990 Sep; 50(17):5234-9. PubMed ID: 2386933
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.
Pisani RJ; Krco CJ; Wold LE; McKean DJ
Am J Clin Pathol; 1989 Oct; 92(4):435-46. PubMed ID: 2552792
[TBL] [Abstract][Full Text] [Related]
15. Cytokine gene expression during the generation of human lymphokine-activated killer cells: early induction of interleukin 1 beta by interleukin 2.
Kovacs EJ; Beckner SK; Longo DL; Varesio L; Young HA
Cancer Res; 1989 Feb; 49(4):940-4. PubMed ID: 2783560
[TBL] [Abstract][Full Text] [Related]
16. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
18. Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody.
Hirte HW; Clark DA; O'Connell G; Rusthoven J; Mazurka J
Cell Immunol; 1992 Jun; 142(1):207-16. PubMed ID: 1534038
[TBL] [Abstract][Full Text] [Related]
19. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
[TBL] [Abstract][Full Text] [Related]
20. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
